文献速递白血病

新型4-mRNA特征预测急性髓系白血病总生存

A novel 4-mRNA signature predicts the overall survival in acute myeloid leukemia.
PubMed 文献 · Am J Hematol · 2021-08-14

该研究在AML与对照样本间鉴定336个差异表达基因及206个代表肿瘤内异质性的基因,用LASSO Cox回归构建由KLF9、ENPP4、TUBA4A、CD247组成的4-mRNA预后特征。高评分与更短总生存、复杂核型及不良突变相关,并在两个独立队列中验证;将其加入2017 ELN风险分类可提高生存预测准确性。

要点

  • 4-mRNA特征由KLF9、ENPP4、TUBA4A和CD247组成,可预测AML总生存。
  • 高评分与更短总生存、复杂核型及不良突变显著相关。
  • 该特征独立于年龄、WBC计数和不良细胞遗传学等传统预后因素。

核心结论

  • 4-mRNA特征可细化AML风险分层并改善预后预测。

研究设计与样本

  • 研究鉴定AML与对照间336个差异表达基因及206个代表AML肿瘤内异质性的基因,采用LASSO Cox回归构建4-mRNA特征,并在两个独立队列中验证。

主要发现

  • 高评分与更短总生存、复杂核型及不良突变显著相关。
  • 将4-mRNA特征加入2017 ELN风险分类可提高AML患者生存预测准确性。
  • 单因素和多因素分析显示该特征独立于年龄、WBC计数和不良细胞遗传学等传统预后因素。
  • 研究探索了高危与低危AML患者结局差异的分子机制。

关键数值与推荐

  • 4-mRNA特征包含KLF9、ENPP4、TUBA4A和CD247。

临床怎么用

  • 可将4-mRNA特征与2017 ELN风险分类结合,用于细化AML患者风险分层和预后判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) is an aggressive cancer of myeloid cells with high levels of heterogeneity and great variability in prognostic behaviors. Cytogenetic abnormalities and genetic mutations have been widely used in the prognostic stratification of AML to assign patients into different risk categories. Nevertheless, nearly half of AML patients assigned to intermediate risk need more precise prognostic schemes. Here, 336 differentially expressed genes (DEGs) between AML and control samples and 206 genes representing the intratumor heterogeneity of AML were identified. By applying a LASSO Cox regression model, we generated a 4-mRNA prognostic signature comprising KLF9, ENPP4, TUBA4A and CD247. Higher risk scores were significantly associated with shorter overall survival, complex karyotype, and adverse mutations. We then validated the prognostic value of this 4-mRNA signature in two independent cohorts. We also proved that incorporation of the 4-mRNA-based signature in the 2017 European LeukemiaNet (ELN) risk classification could enhance the predictive accuracy of survival in patients with AML. Univariate and multivariate analyses showed that this signature was independent of traditional prognostic factors such as age, WBC count, and unfavorable cytogenetics. Finally, the molecular mechanisms underlying disparate outcomes in high-risk and low-risk AML patients were explored. Therefore, our findings suggest that the 4-mRNA signature refines the risk stratification and prognostic prediction of AML patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Chen Z, Song J, Wang W, et al. A novel 4-mRNA signature predicts the overall survival in acute myeloid leukemia. Am J Hematol. 2021. PMID: 34339537. doi:10.1002/ajh.26309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。